[Determination of benzbromarone in serum following combined therapy with allopurinol and benzbromarone (author's transl)].
A rapid method is described for benzbromarone assay in human serum. Protein precipitation is followed by extraction of the active substance. After centrifugation the clear organic layer is evaporated to dryness, redissolved in methanol and injected on a HPLC-column. Detection limits for this method of assay are 0.1 microgram benzbromarone/ml serum. The blood level for therapeutic concentrations lies between 1 and 2.5 microgram/ml. Some pharmacokinetic data were presented. The half-life of benzbromarone is 2.6 h.
D000328:Adult; D000493:Allopurinol / Q000008:administration & dosage*; D001553:Benzbromarone / Q000008:administration & dosage / Q000097:blood*; D001572:Benzofurans / Q000097:blood*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male
D001572:Benzofurans; D004338:Drug Combinations; D001553:Benzbromarone; D000493:Allopurinol
Nachweis von Benzbromaron im Serum bei einer Kombinationsbehandlung mit Allopurinol und Benzbromaron.